| Name | Title | Contact Details |
|---|---|---|
Peter Sperger |
Global Chief Corporate Compliance, Internal Audit, and IT/Cyber Security Officer | Profile |
Afzal Khan |
Global Chief Information Security Officer | Profile |
ALDA Pharmaceuticals Corp. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Developing high-value, global products for patients with significant unmet medical needs in niche indications
Inotiv: (bio)analytical, in vivo, toxicology and molecular pathology services for preclinical drug metabolism in drug development.
X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.